Drug Detail

Information about Caprelsa

Generic Name	Vandetanib
IND	ZD6474
Brand Name (US)	Caprelsa
Manufacturer	AstraZeneca
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Approved for a non-GIST cancer
Indications	Advanced Medullary Thyroid Cancer
Overall Strategy	GIST cell based
Strategy	Block related tumor signal paths
Drug Category	EGFR and VEGF inhibitor

Vandetanib is approved by advanced Medullary Thyroid Cancer. A clinical trial for dSDH GIST patients was conducted by the NIH (2012).
Pediatric-type GIST is thought to overexpress both EGFR and VEGF. Vandetanib inhibits both of these targets.
The trial enrolled 9 patients. Three of the first five patients required dose modification. No partial or complete responses were seen. Two of nine patients had prolonged stable disease, but no partial or complete responses, as a result vandetanib is not considered active in dSDH GIST.